In the past 10 years, positron emission tomography (PET), usually with 18 F-fluoro-2-deoxy-
D-glucose (FDG), has become an important imaging modality in patients with lung cancer …

In the past 5 yrs, positron emission tomography (PET), usually used with 18 F‐fluoro‐2‐
deoxy-glucose (FDG), has become an important imaging modality in lung cancer patients …

Positron emission tomography (PET) represents a dramatic advance in the imaging of lung
cancer. It is valuable for the diagnosis, staging, prognosis, and restaging of disease, and is …

Since its introduction in 1974, positron emission tomography (PET) has gained widespread
use, especially in diagnosis and staging of lung cancer. In this respect, 18F …

Considering the potential of PET imaging for precision medicine and drug development in
lung and other types of cancer, increasing efforts are warranted to standardize PET …

Positron emission tomography (PET) with 18F‐fluoro‐2‐deoxyglucose (FDG) has recently
emerged as a practical and useful imaging modality in patients with lung cancer. Malignant …

Positron emission tomography (PET) is now an important cancer imaging tool, both for
diagnosis and staging, as well as offering prognostic information based on response. This …

Imaging techniques play an essential role in the diagnosis, staging, and follow-up of patients
with lung cancer. Positron emission tomography (PET) has become an important innovation …

Accurate staging is essential to offer the patient the most effective available treatment and
the best estimate of prognosis. In non-small cell lung cancer (NSCLC), surgical resection …

Positron emission tomography (PET) using [18F]-2-deoxy-2-fluoro-d-glucose (FDG) has
emerged as a valuable diagnostic modality in patients with non-small cell lung cancer …